(NASDAQ:ARVN), who have seen the share price tank a massive 86% over a three year period. That might cause some serious doubts about the merits of the initial decision to buy the stock, to put it ...

Amarin Corporation AMRN reported a loss of 3 cents per share for the second quarter of 2025, which was significantly narrower ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Results from the POLARGO trial “reinforce the benefit of adding polatuzumab to chemoimmunotherapy,” said Matthew Matasar, MD.

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected ...

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return ...

SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those ...

The word on The Street in general, suggests a Hold analyst consensus rating for Ramsay Health Care with a $26.63 average price target, implying a 5.8% upside from current levels. In a report issued on ...

This represents a potential first for preclinical evidence of anti-tumor activity by an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model. Furthermore, ARV-393 monotherapy ...

Arvinas' top executive, John Houston, plans to retire after roughly eight years at the helm of the clinical-stage biotechnology company. Arvinas on Wednesday said Houston, who has been president ...

– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of ...

– Arvinas Board of Directors to Lead Search for CEO Replacement – NEW HAVEN, Conn., July 09, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company ...